Over-activation of this pathway in autoimmune and/or inflammatory diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) was recognized early on, and pharmacologic inhibitors of p38 have progressed as far as Phase II clinical trials in these diseases, though with limited success so far (21). The gene discussed is MAPK14; the disease is rheumatoid arthritis.